ES2367576T3 - Nuevos compuestos como moduladores de receptores opioides. - Google Patents
Nuevos compuestos como moduladores de receptores opioides. Download PDFInfo
- Publication number
- ES2367576T3 ES2367576T3 ES05728171T ES05728171T ES2367576T3 ES 2367576 T3 ES2367576 T3 ES 2367576T3 ES 05728171 T ES05728171 T ES 05728171T ES 05728171 T ES05728171 T ES 05728171T ES 2367576 T3 ES2367576 T3 ES 2367576T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- aryl
- optionally substituted
- alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
Abstract
Un compuesto de Formula (I) **Fórmula** en la que: R1 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6, cicloalquilo, heterociclilo, arilalquilo (C1- 6) y heteroarilalquilo (C1-6); en la que cuando R1 es fenilalquilo (C1-6), fenilo esta opcionalmente condensado a un heterociclilo o cicloalquilo; en la que cuando R1 es alquilo C1-2, dicho alquilo C1-2 esta opcionalmente sustituido con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alcoxi C1-6, arilo, cicloalquilo, heterociclilo, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo y carboxi; y adicionalmente, en la que cuando R1 es alquilo C3-6, dicho alquilo C3-6 esta opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en alcoxi C1-6, arilo, cicloalquilo, heterociclilo, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo y carboxi; en la que el cicloalquilo y el heterociclilo de alquilo C1-2 y alquilo C3-6 estan opcionalmente sustituidos con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, hidroxialquilo (C1-6), alcoxi C1-6, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo, carboxi, arilalcoxicarbonilo (C1-6), alcoxicarbonilo C1-6, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1- 6)2aminocarbonilo y aminosulfonilo; ademas, en la que el cicloalquilo y el heterociclilo de R1 estan opcionalmente sustituidos con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, hidroxialquilo (C1-6), alcoxi C1-6, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo, carboxi, arilalcoxicarbonilo (C1-6), alcoxicarbonilo C1-6, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1-6)2aminocarbonilo y aminosulfonilo; ademas, en la que la porcion de arilo y heteroarilo de los sustituyentes R1 arilalquilo (C1-6) y heteroarilalquilo (C1- 6), esta opcionalmente sustituida con uno a tres sustituyentes R11 seleccionados independientemente entre el grupo que consiste en alquilo C1-6; hidroxialquilo (C1-6); alcoxi C1-6; aril C6-10-alquilo (C1-6); aril C6-10-alcoxi (C1-6); arilo C6-10; heteroarilo opcionalmente sustituido con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-4, alcoxi C1-4 y carboxi; cicloalquilo; heterociclilo; ariloxi C6-10; heteroariloxi; cicloalquiloxi; heterocicliloxi; amino; alquilamino C1-6; (alquil C1-6)2amino; cicloalquilaminocarbonilo C3-6; hidroxialquilaminocarbonilo (C1-6); arilaminocarbonilo C6-10 en la que arilo C6-10 esta opcionalmente sustituido con carboxi o alcoxicarbonilo C1-4; heterociclilcarbonilo; carboxi; alcoxicarbonilo C1-6; alcoxicarboniloxi C1-6; alquilcarbonilo C1-6; alquilcarbonilamino C1-6; aminocarbonilo; alquilaminocarbonilo C1-6; (alquil C1- 6)2aminocarbonilo; ciano; halogeno; trifluorometilo; trifluorometoxi; e hidroxi; con la condicion de que no mas de un sustituyente R11 se seleccione entre el grupo que consiste en aril C6-10- alquilo (C1-6); aril C6-10-alcoxi (C1-6); arilo C6-10; heteroarilo opcionalmente sustituido con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-4, alcoxi C1-4 y carboxi; cicloalquilo; heterociclilo; ariloxi C6-10; heteroariloxi; cicloalquiloxi; arilaminocarbonilo C6-10 en la que arilo C6-10 esta opcionalmente sustituido con carboxi o alcoxicarbonilo C1-4; heterociclilcarbonilo y heterocicliloxi; R2 es hidrogeno, alquilo C1-8, hidroxialquilo (C1-8), aril C6-10-alcoxi (C1-6)-alquilo (C1-6) o aril C6-10-alquilo (C1-8); en la que el grupo arilo C6-10 en los sustituyentes que contienen arilo C6-10 de R2 estan opcionalmente sustituidos con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, alcoxi C1-6, hidroxi, amino, alquilamino C1-6, (alquil C1-6)2amino, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1-6)2aminocarbonilo, ciano, fluor, cloro, bromo, trifluorometilo y trifluorometoxi; y, en la que los sustituyentes alquilo C1-6 y alcoxi C1-6 de arilo estan opcionalmente sustituidos con hidroxi, amino, alquilamino C1-6, (alquil C1- 6)2amino o arilo; A es a-1, opcionalmente sustituido con R3 y R5; en la que A-B es N-C; R3 es de uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, arilo, arilalquilo (C1-6), arilalquenilo (C2-6), arilalquinilo (C2-6), heteroarilo, heteroarilalquilo (C1-6), heteroarilalquenilo (C2-6), heteroarilalquinilo (C2-6), amino, alquilamino C1-6, (alquil C1-6)2amino, arilamino, heteroarilamino, ariloxi, heteroariloxi, trifluorometilo y halogeno; en la que el arilo, heteroarilo y el arilo y heteroarilo de arilalquilo (C1-6), arilalquenilo (C2-6), arilalquinilo (C2-6), heteroarilalquilo (C1-6), heteroarilalquenilo (C2-6), heteroarilalquinilo (C2-6), arilamino, heteroarilamino, ariloxi y heteroariloxi, estan opcionalmente sustituidos con uno a cinco sustituyentes fluor o uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, hidroxialquilo (C1-6), alcoxi C1-6, aril C6-10-alquilo (C1-6), aril C6-10-alcoxi (C1-6), arilo C6-10, ariloxi C6-10, heteroarilalquilo (C1-6), heteroarilalcoxi (C1- 6), heteroarilo, heteroariloxi, arilamino C6-10, heteroarilamino, amino, alquilamino C1-6, (alquil C1-6)2amino, carboxialquilamino (C1-6), carboxi, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, alquilcarbonilamino C1-6, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1-6)2aminocarbonilo, carboxialquilaminocarbonilo (C1-6), ciano, halogeno, trifluorometilo, trifluorometoxi, hidroxi, alquilsulfonilo C1-6 y alquilsulfonilamino C1-6; con la condicion de que no mas de uno de dichos sustituyentes en la porcion arilo o heteroarilo de R3 se seleccione entre el grupo que consiste en aril C6-10-alquilo (C1-6), aril C6-10-alcoxi (C1-6), arilo C6-10, ariloxi C6-10, heteroarilalquilo (C1-6), heteroarilalcoxi (C1-6), heteroarilo, heteroariloxi, arilamino C6-10, heteroarilamino; y en la que alquilo C1-6 y alquilo C1-6 de arilalquilo (C1-6) y heteroarilalquilo (C1-6) estan opcionalmente sustituidos con un sustituyente seleccionado entre el grupo que consiste en hidroxi, carboxi, alcoxicarbonilo C1-4, amino, alquilamino C1-6, (alquil C1-6)2amino, aminocarbonilo, alquilaminocarbonilo (C1-4), dialquilaminocarbonilo (C1-4), arilo, heteroarilo, arilamino, heteroarilamino, ariloxi, heteroariloxi, arilalcoxi (C1-4) y heteroarilalcoxi (C1-4); R4 es arilo C6-10 o un heteroarilo seleccionado entre el grupo que consiste en furilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, pirazinilo, indolilo, isoindolilo, indolinilo, benzofurilo, benzotienilo, bencimidazolilo, benztiazolilo, benzoxazolilo, quinolizinilo, quinolinilo, isoquinolinilo y quinazolinilo; en la que R4 esta opcionalmente sustituido con uno a tres sustituyentes R41 seleccionados independientemente entre el grupo que consiste en alquilo (C1-6) opcionalmente sustituido con amino, alquilamino C1-6 o (alquil C1- 6)2amino; alcoxi (C1-6); fenilalcoxi (C1-6); fenilalquilcarboniloxi (C1-6) en la que alquilo C1-6 esta opcionalmente sustituido con amino; un heteroarilalquilcarboniloxi (C1-6) no condensado de 5 miembros; un heteroarilo no condensado de 5 miembros; hidroxi; halogeno; aminosulfonilo; formilamino; aminocarbonilo; alquilaminocarbonilo C1-6 en la que alquilo (C1-6) esta opcionalmente sustituido con amino, alquilamino C1-6 o (alquil C1-6)2amino; (alquil C1-6)2aminocarbonilo en la que cada alquilo (C1-6) esta opcionalmente sustituido con amino, alquilamino C1-6 o (alquil C1-6)2amino; heterociclilcarbonilo en la que heterociclilo es un anillo que contiene nitrogeno de 5-7 miembros y dicho heterociclilo esta unido al carbono carbonilo a traves de un atomo de nitrogeno; carboxi; o ciano; y en la que la porcion fenilo de fenilalquilcarboniloxi (C1-6) esta opcionalmente sustituida con alquilo (C1-6)-alcoxi (C1-6), halogeno, ciano, amino o hidroxi; con la condicion de que no mas de un R41 sea alquilo C1-6 sustituido con alquilamino C1-6 o (alquil C1-6)2amino; aminosulfonilo; formilamino; aminocarbonilo; alquilaminocarbonilo C1-6; (alquil C1-6)2aminocarbonilo; heterociclilcarbonilo; hidroxi; carboxi; o un sustituyente que contiene fenilo o heteroarilo; R5 es un sustituyente en un atomo de nitrogeno del anillo A seleccionado entre el grupo que consiste en hidrogeno y alquilo C1-4; R6 es hidrogeno o alquilo C1-6; R7 es hidrogeno o alquilo C1-6; Ra Rb y se seleccionan independientemente entre el grupo que consiste en hidrogeno, alquilo C1-6 y alcoxicarbonilo C1-6; como alternativa, cuando cada uno de Ra y Rb es distinto de hidrogeno, Ra y Rb se toman opcionalmente junto con el atomo de nitrogeno al que ambos estan unidos para formar un anillo monociclico de cinco a ocho miembros; L es O; y enantiomeros, diastereomeros, racematos y sales farmaceuticamente aceptables del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55334204P | 2004-03-15 | 2004-03-15 | |
US553342P | 2004-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2367576T3 true ES2367576T3 (es) | 2011-11-04 |
Family
ID=34962827
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10182349T Active ES2428008T3 (es) | 2004-03-15 | 2005-03-14 | Moduladores de receptores opioides |
ES16178050T Active ES2705077T3 (es) | 2004-03-15 | 2005-03-14 | Moduladores de receptores opioides |
ES13173454.3T Active ES2596434T3 (es) | 2004-03-15 | 2005-03-14 | Moduladores de receptores opioides |
ES05728171T Active ES2367576T3 (es) | 2004-03-15 | 2005-03-14 | Nuevos compuestos como moduladores de receptores opioides. |
ES12194058.9T Active ES2533176T3 (es) | 2004-03-15 | 2005-03-14 | Proceso para preparar intermedios de compuestos útiles como moduladores de receptores opioides |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10182349T Active ES2428008T3 (es) | 2004-03-15 | 2005-03-14 | Moduladores de receptores opioides |
ES16178050T Active ES2705077T3 (es) | 2004-03-15 | 2005-03-14 | Moduladores de receptores opioides |
ES13173454.3T Active ES2596434T3 (es) | 2004-03-15 | 2005-03-14 | Moduladores de receptores opioides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12194058.9T Active ES2533176T3 (es) | 2004-03-15 | 2005-03-14 | Proceso para preparar intermedios de compuestos útiles como moduladores de receptores opioides |
Country Status (36)
Country | Link |
---|---|
US (8) | US7741356B2 (es) |
EP (5) | EP3112352B1 (es) |
JP (1) | JP4778954B2 (es) |
KR (1) | KR101166342B1 (es) |
CN (2) | CN102786476B (es) |
AR (2) | AR048269A1 (es) |
AT (1) | ATE516274T1 (es) |
AU (1) | AU2005224091B2 (es) |
BR (1) | BRPI0508820B8 (es) |
CA (1) | CA2560047C (es) |
CR (1) | CR8655A (es) |
CY (3) | CY1111927T1 (es) |
DK (5) | DK2573068T3 (es) |
EC (1) | ECSP066856A (es) |
ES (5) | ES2428008T3 (es) |
HK (4) | HK1099016A1 (es) |
HR (4) | HRP20110694T1 (es) |
HU (2) | HUE029852T2 (es) |
IL (3) | IL178040A (es) |
LT (2) | LT2653465T (es) |
LU (1) | LUC00007I2 (es) |
ME (3) | ME02540B (es) |
MX (1) | MXPA06010642A (es) |
MY (1) | MY146972A (es) |
NL (1) | NL300865I2 (es) |
NO (3) | NO338203B1 (es) |
NZ (1) | NZ549842A (es) |
PH (1) | PH12012501640A1 (es) |
PL (4) | PL1725537T3 (es) |
PT (4) | PT1725537E (es) |
RS (4) | RS51995B (es) |
SI (4) | SI1725537T1 (es) |
TW (1) | TWI361069B (es) |
UA (1) | UA86053C2 (es) |
WO (1) | WO2005090315A1 (es) |
ZA (1) | ZA200608587B (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
ATE516274T1 (de) | 2004-03-15 | 2011-07-15 | Janssen Pharmaceutica Nv | Neue verbindungen als modulatoren des opioidrezeptors |
CN1984879B (zh) | 2004-05-14 | 2011-07-27 | 詹森药业有限公司 | 甲酰胺基阿片样化合物 |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
EP1863764A1 (en) * | 2005-03-14 | 2007-12-12 | Janssen Pharmaceutica, N.V. | Process for the preparation of opioid modulators |
ATE511502T1 (de) * | 2005-12-14 | 2011-06-15 | Bristol Myers Squibb Co | Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren |
JP5473334B2 (ja) * | 2005-12-23 | 2014-04-16 | ジーランド ファーマ アクティーゼルスカブ | 修飾リジン模倣化合物 |
RU2473565C2 (ru) | 2006-04-07 | 2013-01-27 | Аерпио Терапетикс, Инк. | АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (HPTPβ), И ИХ ИСПОЛЬЗОВАНИЕ |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
EP2468724B1 (en) * | 2006-12-21 | 2015-11-18 | Zealand Pharma A/S | Synthesis of pyrrolidine compounds |
JP5702140B2 (ja) * | 2007-07-09 | 2015-04-15 | フリエツクス・フアーマシユーテイカルズ・インコーポレーテツド | 5−({[2−アミノ−3−(4−カルバモイル−2,6−ジメチル−フェニル)−プロピオニル]−[1−(4−フェニル−1h−イミダゾール−2−イル)−エチル]−アミノ}−メチル)−2−メトキシ−安息香酸の新規な結晶及び製造方法 |
JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
TWI468375B (zh) | 2008-10-27 | 2015-01-11 | Janssen Pharmaceutica Nv | 製備經保護之l-丙胺酸衍生物之方法 |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
JP5198220B2 (ja) * | 2008-11-13 | 2013-05-15 | 東ソ−・エフテック株式会社 | アミノ酸誘導体の製造方法 |
MY160399A (en) | 2009-07-06 | 2017-03-15 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
EP2524912A1 (en) | 2011-05-16 | 2012-11-21 | Bionomics Limited | Amine derivatives |
JP6254075B2 (ja) | 2011-05-16 | 2017-12-27 | バイオノミックス リミテッド | カリウムチャネル遮断剤としてのアミン誘導体 |
WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
US9447079B2 (en) * | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
DK2970132T3 (da) | 2013-03-14 | 2020-12-21 | Epizyme Inc | Argininmethyltransferaseinhibitorer og anvendelser deraf |
WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
IS2977B (is) | 2015-02-23 | 2017-07-15 | Actavis Group Ptc Ehf. | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni |
US10702498B2 (en) | 2015-07-09 | 2020-07-07 | The Regents Of The University Of California | MU opioid receptor modulators |
US10314819B2 (en) | 2015-07-23 | 2019-06-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of Eluxadoline |
CN108026032B (zh) * | 2015-09-11 | 2020-09-29 | 株式会社钟化 | 光学活性4-氨基甲酰基-2,6-二甲基苯基丙氨酸衍生物的制造方法 |
KR20180054677A (ko) | 2015-09-23 | 2018-05-24 | 에르피오 세러퓨틱스 인코포레이티드 | Tie-2의 활성화제로 안내압을 치료하는 방법 |
CN105250232B (zh) * | 2015-09-29 | 2018-08-14 | 江苏汇智知识产权服务有限公司 | 一种伊卢多啉肠溶片及其制备方法 |
WO2017114446A1 (zh) * | 2015-12-31 | 2017-07-06 | 苏州晶云药物科技有限公司 | 艾沙度林的新晶型及其制备方法 |
CN107129444B (zh) * | 2016-02-29 | 2018-08-31 | 尚科生物医药(上海)有限公司 | (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法 |
EP3272741A1 (en) | 2016-07-21 | 2018-01-24 | Euticals S.P.A. | New stable solvate crystalline forms of eluxadoline |
CN105777584B (zh) * | 2016-03-28 | 2018-01-02 | 成都伊诺达博医药科技有限公司 | 丙氨酸衍生物的制备方法 |
CN105693554B (zh) * | 2016-04-06 | 2017-08-08 | 成都伊诺达博医药科技有限公司 | 丙氨酸衍生物的制备方法 |
WO2017191650A1 (en) * | 2016-05-03 | 2017-11-09 | Msn Laboratories Private Limited | Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof |
WO2017208156A1 (en) * | 2016-05-30 | 2017-12-07 | Sun Pharmaceutical Industries Limited | A process for the preparation of eluxadoline |
US10822308B2 (en) * | 2016-06-23 | 2020-11-03 | Sun Pharmaceutical Industries Limited | Processes for the preparation of eluxadoline |
WO2018020450A2 (en) | 2016-07-28 | 2018-02-01 | Lupin Limited | Process for the preparation of eluxadoline |
CZ2016548A3 (cs) | 2016-09-07 | 2018-03-14 | Zentiva, K.S. | Pevné formy eluxadolinu |
WO2018047131A1 (en) * | 2016-09-09 | 2018-03-15 | Sun Pharmaceutical Industries Limited | Amorphous eluxadoline |
EP3515434A4 (en) | 2016-09-20 | 2020-02-26 | Sun Pharmaceutical Industries Limited | METHOD FOR PRODUCING ELUXADOLIN |
EP3573958A1 (en) | 2017-01-27 | 2019-12-04 | Quimica Sintetica, S.A. | Eluxadoline crystalline forms and processes for their preparation |
WO2018138272A1 (en) | 2017-01-27 | 2018-08-02 | Quimica Sintetica, S. A. | Eluxadoline crystalline form and process for the preparation thereof |
CN110709096B (zh) | 2017-05-05 | 2023-10-31 | 泽兰德制药公司 | 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用 |
WO2019008604A1 (en) | 2017-07-07 | 2019-01-10 | Cipla Limited | NEW FORMS OF MU-OPIOID RECEPTOR AGONIST |
WO2019144805A1 (zh) * | 2018-01-25 | 2019-08-01 | 四川科伦博泰生物医药股份有限公司 | 取代的苯乙胺化合物及其制备方法和用途 |
WO2019197274A1 (en) | 2018-04-09 | 2019-10-17 | Quimica Sintetica, S. A. | Process for the preparation of opioid modulators |
US20210251964A1 (en) | 2018-08-20 | 2021-08-19 | Allergan Holdings Unlimited Company | Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
PL3659433T3 (pl) * | 2018-11-30 | 2021-11-08 | Phytobiotics Futterzusatzstoffe Gmbh | System analizowania obrazów wydzielin zwierzęcych |
CN111377832A (zh) * | 2018-12-27 | 2020-07-07 | 江苏联昇化学有限公司 | 一种伊卢多啉中间体制备的新方法 |
WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
WO2021198780A1 (en) | 2020-03-30 | 2021-10-07 | Allergan Holdings Unlimited Company | Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
IL300110A (en) * | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Chiral synthesis of RAF inhibitors in compressed cyclics |
US11850319B2 (en) | 2020-09-29 | 2023-12-26 | Abl Ip Holding Llc | Techniques for directing ultraviolet energy towards a moving surface |
US20220096676A1 (en) | 2020-09-29 | 2022-03-31 | Abl Ip Holding Llc | Techniques for Directing Ultraviolet Energy Towards a Moving Surface |
CN114163348A (zh) * | 2020-11-27 | 2022-03-11 | 成都泰蓉生物科技有限公司 | 一种氨酰基取代的l-苯丙氨酸的合成方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD142804A3 (de) * | 1977-11-07 | 1980-07-16 | Wagner Guenter | Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden |
US4879398A (en) * | 1987-12-31 | 1989-11-07 | Monsanto Company | Process for producing 2,6-disubstituted tyrosine |
SE9402880D0 (sv) | 1994-08-30 | 1994-08-30 | Astra Ab | New peptide derivatives |
IL116923A (en) | 1995-01-27 | 2000-09-28 | Novo Nordisk As | Compounds with growth hormone releasing properties and pharmaceutical compositions containing them |
US5565568A (en) | 1995-04-06 | 1996-10-15 | Eli Lilly And Company | 2-acylaminopropanamides as tachykinin receptor antagonists |
HUP9802036A3 (en) | 1995-04-13 | 1999-06-28 | Aventis Pharmaceuticals Inc Br | Novel substituted piperazine derivatives having tachykinin receptor antagonists activity, process for producing them an pharmaceutical compositions containing them |
AU6772996A (en) | 1995-08-21 | 1997-03-12 | Eli Lilly And Company | 2-acylaminopropanamides as growth hormone secretagogues |
WO1997019908A1 (en) | 1995-11-29 | 1997-06-05 | Nihon Nohyaku Co., Ltd. | Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides |
US5792760A (en) | 1997-04-23 | 1998-08-11 | Eli Lilly And Company | Bisindoles as tachykinin receptor antagonists |
IT1304898B1 (it) | 1998-09-08 | 2001-04-05 | Menarini Ricerche Spa | Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche |
PT1055665E (pt) * | 1999-05-28 | 2004-03-31 | Pfizer Prod Inc | Derivados da 3-(3-hidroxifenil)-3-amino-propionamida |
FR2796643B1 (fr) | 1999-07-22 | 2005-04-29 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique |
GB0021419D0 (en) | 2000-08-31 | 2000-10-18 | Oxford Glycosciences Uk Ltd | Compounds |
US20020072017A1 (en) * | 2000-10-19 | 2002-06-13 | Hudnall Phillip Montgomery | Stabilized p-phenylenediamine-type photographic color developers in free base form |
EP1392291B1 (en) | 2000-10-30 | 2007-05-30 | Janssen Pharmaceutica N.V. | Tripeptidyl peptidase inhibitors |
AU2002346994B2 (en) * | 2001-10-15 | 2007-09-06 | Janssen Pharmaceutica N.V. | Novel substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
US7041681B2 (en) | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
ATE516274T1 (de) * | 2004-03-15 | 2011-07-15 | Janssen Pharmaceutica Nv | Neue verbindungen als modulatoren des opioidrezeptors |
EP1753749B1 (en) * | 2004-05-03 | 2014-07-30 | Janssen Pharmaceutica NV | Novel indole derivatives as selective androgen receptor modulators (sarms) |
EP1863764A1 (en) * | 2005-03-14 | 2007-12-12 | Janssen Pharmaceutica, N.V. | Process for the preparation of opioid modulators |
-
2005
- 2005-03-14 AT AT05728171T patent/ATE516274T1/de active
- 2005-03-14 UA UAA200609824A patent/UA86053C2/ru unknown
- 2005-03-14 PL PL05728171T patent/PL1725537T3/pl unknown
- 2005-03-14 SI SI200531383T patent/SI1725537T1/sl unknown
- 2005-03-14 RS RS20110446A patent/RS51995B/en unknown
- 2005-03-14 BR BRPI0508820A patent/BRPI0508820B8/pt not_active IP Right Cessation
- 2005-03-14 ME MEP-2016-232A patent/ME02540B/me unknown
- 2005-03-14 ES ES10182349T patent/ES2428008T3/es active Active
- 2005-03-14 SI SI200532091A patent/SI2653465T1/sl unknown
- 2005-03-14 RS RS20130371A patent/RS52933B/en unknown
- 2005-03-14 EP EP16178050.7A patent/EP3112352B1/en active Active
- 2005-03-14 EP EP05728171A patent/EP1725537B1/en active Active
- 2005-03-14 WO PCT/US2005/008339 patent/WO2005090315A1/en active Application Filing
- 2005-03-14 CN CN201210277845.6A patent/CN102786476B/zh not_active Expired - Fee Related
- 2005-03-14 PL PL13173454T patent/PL2653465T3/pl unknown
- 2005-03-14 MX MXPA06010642A patent/MXPA06010642A/es active IP Right Grant
- 2005-03-14 JP JP2007503986A patent/JP4778954B2/ja not_active Expired - Fee Related
- 2005-03-14 ES ES16178050T patent/ES2705077T3/es active Active
- 2005-03-14 ES ES13173454.3T patent/ES2596434T3/es active Active
- 2005-03-14 ME MEP-2015-36A patent/ME02221B/me unknown
- 2005-03-14 MY MYPI20051060A patent/MY146972A/en unknown
- 2005-03-14 RS RS20150204A patent/RS54199B1/en unknown
- 2005-03-14 ME MEP-2013-97A patent/ME01601B/me unknown
- 2005-03-14 PT PT05728171T patent/PT1725537E/pt unknown
- 2005-03-14 CA CA2560047A patent/CA2560047C/en active Active
- 2005-03-14 DK DK12194058.9T patent/DK2573068T3/en active
- 2005-03-14 CN CN200580014571XA patent/CN1950342B/zh not_active Expired - Fee Related
- 2005-03-14 DK DK05728171.9T patent/DK1725537T3/da active
- 2005-03-14 EP EP10182349.0A patent/EP2298744B1/en active Active
- 2005-03-14 LT LTEP13173454.3T patent/LT2653465T/lt unknown
- 2005-03-14 ES ES05728171T patent/ES2367576T3/es active Active
- 2005-03-14 TW TW094107612A patent/TWI361069B/zh not_active IP Right Cessation
- 2005-03-14 SI SI200531934T patent/SI2573068T1/sl unknown
- 2005-03-14 NZ NZ549842A patent/NZ549842A/en not_active IP Right Cessation
- 2005-03-14 EP EP12194058.9A patent/EP2573068B9/en active Active
- 2005-03-14 PL PL12194058T patent/PL2573068T3/pl unknown
- 2005-03-14 US US11/079,647 patent/US7741356B2/en active Active
- 2005-03-14 EP EP13173454.3A patent/EP2653465B1/en active Active
- 2005-03-14 KR KR1020067021231A patent/KR101166342B1/ko active IP Right Grant
- 2005-03-14 DK DK16178050.7T patent/DK3112352T3/en active
- 2005-03-14 DK DK13173454.3T patent/DK2653465T3/da active
- 2005-03-14 RS RS20160843A patent/RS55122B1/sr unknown
- 2005-03-14 DK DK10182349.0T patent/DK2298744T3/da active
- 2005-03-14 HU HUE13173454A patent/HUE029852T2/en unknown
- 2005-03-14 PT PT101823490T patent/PT2298744E/pt unknown
- 2005-03-14 PT PT131734543T patent/PT2653465T/pt unknown
- 2005-03-14 SI SI200531771T patent/SI2298744T1/sl unknown
- 2005-03-14 ES ES12194058.9T patent/ES2533176T3/es active Active
- 2005-03-14 PL PL10182349T patent/PL2298744T3/pl unknown
- 2005-03-14 PT PT121940589T patent/PT2573068E/pt unknown
- 2005-03-14 AU AU2005224091A patent/AU2005224091B2/en not_active Ceased
- 2005-03-15 AR ARP050101007A patent/AR048269A1/es active IP Right Grant
-
2006
- 2006-09-12 IL IL178040A patent/IL178040A/en active IP Right Grant
- 2006-09-15 EC EC2006006856A patent/ECSP066856A/es unknown
- 2006-09-25 CR CR8655A patent/CR8655A/es unknown
- 2006-10-13 NO NO20064660A patent/NO338203B1/no not_active IP Right Cessation
- 2006-10-13 ZA ZA2006/08587A patent/ZA200608587B/en unknown
-
2007
- 2007-05-28 HK HK07105593.3A patent/HK1099016A1/xx not_active IP Right Cessation
- 2007-10-17 HK HK07111210.4A patent/HK1105967A1/xx not_active IP Right Cessation
- 2007-10-24 US US11/877,747 patent/US7786158B2/en active Active
-
2010
- 2010-07-19 US US12/838,825 patent/US8344011B2/en active Active
-
2011
- 2011-09-19 HK HK11109830.2A patent/HK1155726A1/xx not_active IP Right Cessation
- 2011-09-28 HR HR20110694T patent/HRP20110694T1/hr unknown
- 2011-10-10 CY CY20111100967T patent/CY1111927T1/el unknown
-
2012
- 2012-08-14 PH PH12012501640A patent/PH12012501640A1/en unknown
- 2012-11-30 US US13/690,041 patent/US8609709B2/en active Active
-
2013
- 2013-02-26 IL IL224908A patent/IL224908A/en active IP Right Grant
- 2013-08-22 HR HRP20130800TT patent/HRP20130800T1/hr unknown
- 2013-09-27 HK HK13111031.3A patent/HK1184432A1/xx not_active IP Right Cessation
- 2013-10-03 US US14/045,008 patent/US8772325B2/en active Active
- 2013-11-14 IL IL229444A patent/IL229444A/en active IP Right Grant
-
2014
- 2014-04-11 AR ARP140101566A patent/AR095848A2/es unknown
- 2014-05-20 US US14/282,828 patent/US9205076B2/en active Active
-
2015
- 2015-03-18 HR HRP20150305TT patent/HRP20150305T1/hr unknown
- 2015-10-12 US US14/880,597 patent/US9700542B2/en active Active
-
2016
- 2016-05-30 NO NO20160916A patent/NO20160916A1/no not_active Application Discontinuation
- 2016-10-12 HR HRP20161331TT patent/HRP20161331T1/hr unknown
- 2016-10-12 CY CY20161101019T patent/CY1118096T1/el unknown
-
2017
- 2017-02-23 NO NO2017007C patent/NO2017007I2/no unknown
- 2017-03-01 LT LTPA2017005C patent/LTC1725537I2/lt unknown
- 2017-03-01 LU LU00007C patent/LUC00007I2/fr unknown
- 2017-03-02 HU HUS1700010C patent/HUS1700010I1/hu unknown
- 2017-03-08 CY CY2017008C patent/CY2017008I2/el unknown
- 2017-03-10 NL NL300865C patent/NL300865I2/nl unknown
- 2017-06-07 US US15/616,358 patent/US10213415B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2367576T3 (es) | Nuevos compuestos como moduladores de receptores opioides. | |
AR069512A1 (es) | Pirazolopirimidinas sustituidas para el tratamiento de trastornos del snc. composiciones farmaceuticas | |
HRP20100194T8 (en) | Peri condensed tricyclic compounds useful as antibacterial agents | |
RU2404163C2 (ru) | Производные 2,3,4,9-тетрагидро-1h-карбазола в качестве антагонистов рецептора crth2 | |
AR076381A1 (es) | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
RS50380B (sr) | Inhibitori tirozin kinaze | |
HRP20080477T3 (en) | Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors | |
JP2015517981A5 (es) | ||
HRP20080022T3 (en) | Pyrrolopyridine derivatives and their use as crth2 antagonists | |
RS52545B (en) | INHIBITORI PROTEIN APOPTOZE (IAP) | |
AR049696A1 (es) | Derivados de indol | |
AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
JP2002524570A5 (ja) | Mdm2およびp53間相互作用の阻害剤としてのピペラジン−4−フェニル誘導体 | |
AR036041A1 (es) | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen | |
CO6150176A2 (es) | Derivados de bencimidazol utiles en el tratamiento de los trastornos relacionados con el receptor vaniloide trpv1 | |
JP2010526800A5 (es) | ||
HRP20090533T1 (en) | Indolyl derivatives as liver-x-receptor modulators | |
AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
JP2008536876A5 (es) | ||
JP2007529527A5 (es) | ||
TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
AR050953A1 (es) | Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales | |
AR068061A1 (es) | Derivados de bisamida biciclicos utiles como pesticidas |